Answers are grounded in this paper and cite their sources.
BACKGROUND: Busulfan and cyclophosphamide (BuCy) is the standard myeloablative conditioning regimen for patients with acute myeloblastic leukemia (AML) undergoing allogeneic hematopoietic stem-cell transplantation (allo-HSCT). Fludarabine and busulfan (FluBu) conditioning seems to have similar efficacy with less toxicity. AIMS AND METHODS: Descriptive retrospective study conducted on patients with AML who underwent geno-identical allo-HSCT between January 2011 and December 2022. Patients received a myeloablative conditioning with either BuCy2 orFluBu4. The objective was to compare the efficacy and safety of this regimens. Both regimens yield comparable toxicities. CONCLUSION: Myeloablative FluBu4 conditioning appeared to achieve clinical outcomes similar to BuCy2 and may be considered as a possible alternative for patients at high risk of NRM.
No takes yet. Share an insight, caveat, or question.
N et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: